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Somatically acquired mutations in the epidermal growth factor receptor (EGFR) gene in lung cancer are associated with significant
clinical responses to gefitinib, a tyrosine kinase inhibitor that targets EGFR. We screened the EGFR in 469 resected tumours of
patients with lung cancer, which included 322 adenocarcinomas, 102 squamous cell carcinomas, 27 large cell carcinomas, 13 small cell
carcinomas, and five other cell types. PCR with a specific condition was performed to identify any deletion in exon 19, while mutant-
allele-specific amplification was performed to identify a mutation in codon 858 of exon 21. EGFR mutations were found in 136 cases
(42.2%) with adenocarcinoma, in one case with large cell carcinoma, and in one case with pleomorphic carcinoma. An in-frame
deletion in exon 19 was found in 62 cases while an L858R mutation was found in 77 cases. In the 322 cases with adenocarcinoma,
these mutations were more frequently found in women than in men (P¼0.0004), in well differentiated tumours than in poorly
differentiated tumours (P¼0.0014), and in patients who were never smokers than in patients who were current/former smokers
(Po0.0001). The mutation was more frequently observed in patients who smoked p20 pack-year, and in patients who quit at least
20 years before the date of diagnosis for lung cancer. The K-ras mutations were more frequently found in smokers than in never
smokers, and in high-dose smokers than in low-dose smokers. In conclusion, the mutations within the tyrosine kinase domain of EGFR
were found to specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.
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Lung cancer is the leading causes of cancer-related death
throughout the world, and also in Japanese from 1998. Although
improvement of diagnostic technologies, more than 50% of
patients present locally advanced or distant metastatic disease,
which prognosis is still not satisfactory, because lung cancer is
highly chemoresistant to most currently available chemo-
therapeutic agents. Therefore, the development of new modalities
of treatment is important to improve the cure rate for lung cancer.
The epidermal growth factor receptor (EGFR), which induces
malignant tumour via three major mechanisms such as over-
expression (Brabender et al, 2001; Hirsch et al, 2003), amplifica-
tion (Shiraishi et al, 1989) and mutational activation (Downward
et al, 1984), appears to be molecular target for therapeutic
development. EGFR is a 170 kilodaltons (kDa) membrane-bound
protein encoded by 28 exons on chromosome 7p12, and has a
tyrosine kinase activity after binding of several specific ligands to
the extracellular domain. These phosphorylated tyrosines lead to
the activation of the downstream pathways of EGFR thus resulting
in cell proliferation, differentiation, migration/motility, protection
from apoptosis, or angiogenesis (Roskoski, 2004; Sordella et al,
2004; Baselga and Arteaga, 2005). EGFR-tyrosine kinase has
become an attractive target for the treatment of non-small cell
lung cancer (NSCLC), and agents targeting this receptor, including
gefitinib, erlotinib, and cetuximab, are being investigated. Gefitinib
is an orally active small molecule drug with evidence of an
antitumour activity in NSCLC. In two clinical phase II trials,
therapeutic response to the tyrosine kinase inhibitor (gefitinib)
was predominantly observed in Japanese patients than European
and US patients (Fukuoka et al, 2003; Kris et al, 2003). A clinical
complete or partial response was especially observed most
frequently in women, in nonsmoker, in patients with adeno-
carcinoma.
In 2004 three groups demonstrated the EGFR TK domain
mutations in NSCLC and showed a striking correlation between
the gefitinib sensitivity and TK domain mutations (Lynch et al,
2004; Paez et al, 2004; Pao et al, 2004). Subsequently, many reports
demonstrated that the mutations of EGFR gene are detected in
two specific regions such as an in-frame deletion in exon 19 and a
missense mutation at the second nucleotide of codon 858 in exon
21 (Huang et al, 2004; Kosaka et al, 2004; Lynch et al, 2004; Paez
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set al, 2004; Pao et al, 2004; Shigematsu et al, 2005; Tokumo et al,
2005). In vitro studies expressing the alleles with these hot spot
mutations suggest that mutant EGFRs selectively activate Akt and
STAT signaling pathways, which promote cell survival, but have no
effect on MAPK signaling, which induces proliferation (Sordella
et al, 2004; Tracy et al, 2004). The ability to phosphorylate specific
tyrosine residues in EGFR also appears to be inhibited by gefitinib
or erlotinib at lower doses of drugs than that required for wild-type
EGFR (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004).
Theoretically, these mutations could all result in conformation
changes that lead to increased activity as well as TKI sensitivity
(Gazdar et al, 2004; Lynch et al, 2004; Paez et al, 2004). These
EGFR mutations were significantly more frequent in East Asian
patients than in Caucasian patients (Paez et al, 2004; Marchetti
et al, 2005; Shigematsu et al, 2005). These two mutations were
found in about 90% of all cases with EGFR mutations, therefore,
we focused on two hot spots of mutation in EGFR TK domain.
In this study, we analysed the EGFR mutations in exons 19 and
21 by simple screening methods based on PCR in a large scale of
Japanese patients with lung cancer, and investigated the clinical
significance of these mutations.
MATERIALS AND METHODS
Patients
Tumour specimens were obtained from 469 consecutive patients
with primary lung cancer and were stored according to protocols
approved by the Institutional Review Board of the University of
Occupational and Environmental Health and patients’ written
informed consent, from April 1996 to May 2005. The samples used
in this study were obtained during surgical procedures from
primary lung cancer patients with stage I–IV, according to the
TNM classification revised in 1997 by the International Union
Against Cancer (UICC). They included 322 adenocarcinomas, 102
squamous cell carcinomas, 27 large cell carcinomas, 13 small cell
carcinomas, two pleomorphic carcinoma, one adenosquamous cell
carcinoma, one carcinoid tumour, and one spindle carcinoma.
They consisted of 302 men and 167 women ranging in age from 19
to 91 (average 66.2) years. One hundred seventy three had stage IA
disease, 86 had stage IB, 11 had stage IIA, 54 had stage IIB, 73 had
stage IIIA, 50 had stage IIIB, and 22 had stage IV disease. There
were 138 never smokers and 331 ever smokers including 114
former and 217 current smokers (Table 1). In adenocarcinoma
patients, there were 129 never smokers, 70 former smokers and 123
current smokers. Other clinicopathological features in patients
with adenocarcinoma were shown in Table 2. The current smokers
included patients who had stopped smoking less than 3 years
previously, while former smokers meant that the duration since
they quit smoking was more than 3 years.
DNA extraction and sequencing analyses of the EGFR
Genomic DNA was extracted and purified from either fresh frozen
tumours or tumours embedded in paraffin blocks. At first, in 20
samples, six exons of the TK domain (exons 18–23) were amplified
using primers described in Lynch et al (2004) and uncloned PCR
fragments were directly sequenced and analysed in both sense and
antisense directions for the mutations using Applied Biosystems
PRISM dye terminator cycle sequencing method with ABI PRISM
3100 (Applied Biosystems, Foster City, CA, USA)(Uramoto et al,
2006). The positive samples with mutations in exons 19 or 21
detected by sequencing were used as a positive control for
screening methods described hereafter.
Detection of in-frame deletion in exon 19 by simple
screening method
For detection of the in-frame deletion in exon 19, primers were
constructed in order to make 147bp product, when the allele was
wild-type. The primer sequences are 50-GTCTTCCTTCTCTCTCT
GTCATAG-30 as a sense and 50-CCACACAGCAAAGCAGAAACTC
AC-30 as an antisense. PCR assay was carried out in 25-ml reaction
mixtures containing 1-ml of genomic DNA using Taq DNA poly-
merase (TaKaRa Taq, TaKaRa, Shiga, Japan) for 35 cycles at 641C
for annealing, and the PCR products were run on electrophoresis
in a 4% agarose gel containing 0.5mg/ml ethidium bromide and
visualised under UV (Figure 1A).
Detection of point mutation in exon 21 by
mutant-allele-specific amplification (MASA)
The 30-ends of 22-bp oligonucleotides used as PCR primers
corresponded to G for T of EGFR codon 858. That is, the sense-
primer sequence for wild type was 50-TCAAGATCACAGATTTT
GGGCT, and that for L858R mutation was 50-TCAAGATCACAGAT
TTTGGGCG. The antisense primer for both wild type and mutant
type was 50-CATCCTCCCCTGCATGTGTTAAAC (Figure 2). PCR
assays were carried out for 38 cycles at 661C for annealing. The
Table 1 Clinicopathological features in relation to EGFR mutations in patients with lung cancer
Variables Category n EGFR mutation (%) Exon 19 deletion Exon 21 L858R
Gender Male 302 62
a 20.5% 34 29
Female 167 76 45.5% 28 48
Histology Adenocarcinoma 322 136
a 42.2% 62 75
Squamous cell ca. 102 0 0.0%
Large cell ca. 27 1 3.7% 1
Small cell ca. 13 0 0.0%
Pleomorphic ca. 2 1 50.0% 1
Adenosquamous ca. 1 0 0.0%
Carcinoid tumour 1 0 0.0%
Spindle cell ca. 1 0 0.0%
Smoking Never 138 74
a 53.6% 29 46
Former
b 114 31 27.2% 18 13
Current 217 33 15.2% 15 18
Total 469 138
a 29.4% 62 77
aOne case had mutations in both exons 19 and 21.
bFormer smokers are defined persons who stopped smoking more than 3 years previously.
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sPCR products were run on electrophoresis in a 2% agarose gel
containing 0.5mg/ml ethidium bromide and visualised under UV.
To confirm the sensitivity of this method, exon 21 was amplified in
the mixture of DNA solution of diluted mutation-positive DNA
and wild-type DNA.
Detection of K-ras mutation using PCR-based designed
RFLP
For the detection of K-ras codon 12 mutations, we used our
previously described designed RFLP method (Sugio et al, 1994;
Sugio et al, 1997). Briefly, a sense-mismatched primer was used to
introduce a new restriction site into the PCR product derived from
wild-type allele. The newly introduced restriction sites were BstNI
for screening for codon 12. Wild-type alleles were digested and
they yielded a smaller product (77bp) than mutant forms (97bp),
which were digestive-resistant. The sense-primer sequence was
50-AAACTTGTGGTAGTTGGACCT, and the antisense primer was
50-CTATTGTTGGATCATATTCG.
Statistical analyses
We used the w
2 test and Fisher’s exact tests to assess the
relationship between EGFR gene mutations and each of the
Table 2 Clinicopathological features in relation to EGFR mutations in patients with adenocarcinoma
Variables Category n EGFR mutation (%) P-value Exon 19 deletion Exon 21 L858R P-value
Gender Male 179 60
a 33.5% 0.0004 34 27 0.0272
Female 143 76 53.1% 28 48
Age o66 132 57 43.2% 0.7746 31 26 0.0699
X66 190 79 41.6% 31 49
Differentiation Well 117 63 53.8% 0.0014
b 30 33 40.1
Moderate 145 61
a 42.1% 27 35
Poorly 47 9 19.1% 3 6
Unclassified 13 3 23.1% 2 1
pStage IA 141 73 51.8% n.s. 30 43 40.1
IB 60 16 26.7% 6 10
IIA 7 3 42.9% 1 2
IIB 25 7 28.0% 1 6
IIIA 39 13 33.3% 8 5
IIIB 35 18
a 51.4% 13 6
IV 15 6 40.0% 3 3
Smoking Never 129 74
a 57.4% o0.0001 29 46 0.0884
Smoker 193 62 32.1% 33 29
Former
c 70 31 44.3% 0.0063 18 13 40.1
Current 123 31 25.2% 15 16
K-ras Wild-type 293 136
a 46.4% o0.0001 62 75
Mutation 29 0 0.0% 0 0
Total 322 136
a 42.2% 62 75
aOne case had mutations in both exons 19 and 21.
bWell vs others.
cFormer smokers are defined persons who stopped smoking more than 3 years previously.
Exon 19
gcagcatgtggcaccatctcacaattgccagttaacgtcttccttctctctctgtcatag
740
G   L   W   I   P   E   G   E   K   V   K   I   P   V   A   I   K
GGA CTC TGG ATC CCA GAA GGT GAG AAA GTT AAA ATT CCC GTC GCT ATC AAG
746             750                                         760
E   L   R   E   A   T   S   P   K   A   N   K   E   I   L   D
GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC AAG GAA ATC CTC GAT
gtgagtttctgctttgctgtgtgggggtccatggctctgaacctcaggcccaccttttct
B
A
Wild type: 147 bp
Size
marker PC b e
Samples
200 bp
100 bp Deletion type
f d c a
Figure 1 (A) PCR for detection of deletion in exon 19. The primers of PCR for detection of deletion in exon 19 were shown as arrow. (B) Agarose gel
electrophoresis (4%). The PCR products were applied in 4% of agarose gel. The upper band shows wild-type allele as 147bp, whereas shorter band was
shown as a deletion allele in exon 19. PC: DNA as positive control which has 15bp deletion (E746-A750del) confirmed by sequencing, a–b: positive
samples for deletion, c–f: negative for deletion.



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sclinicopathological features. The Kaplan–Meier method was used
to estimate the probability of survival, and survival differences
were analysed by the log-rank test. All statistical tests were two
sided, and P-values of less than 0.05 were considered statistically
significant.
RESULTS
Exon 19 and 21 mutations in EGFR gene by screening
method
PCR products in exon 19 revealed a 147bp band when the allele
was a wild type, and a shorter band when the allele was a deletion
type, which were clearly separated in 4% agarose gel shown in
Figure 1. In DNA samples which showed shorter band by this
screening method, the exon 19 was amplified and directly
sequenced. Next, the DNA showed an in-frame deletion, namely,
a 15 base deletion from codon 746 to 750. We made 132, 135, and
138bp PCR-products and analysed these products mixed with
147bp product by agarose gel electrophoresis, as a result, a 12bp
difference was clearly detectable while 9bp difference was
suspicious. Therefore, this screening method was suitable to detect
at least more than 12bp deletion in exon 19.
To detect a point mutation of the second base of codon 858 in
exon 21, MASA technique was performed as shown in Figure 2A.
At first, exon 21 was amplified using a primer to detect a mutation
of the second base of codon 858 for DNA samples with the
mutation (L858R) or with only wild type, which was previously
confirmed by sequencing. Agarose gel electrophoresis showed only
the DNA sample with mutation to reveal a band, under stringent
PCR conditions. Next, we used a DNA derived from cell line
(G603L)(Sugaya et al, 2002) with an L858R mutation confirmed by
sequencing (Figure 2B), as a positive control. To confirm the
sensitivity of the MASA method, PCR was performed in the
mixture of diluted mutation-positive DNA with wild-type DNA. As
shown in Figure 2C, a mutant allele was detected in the mixture of
10
 3 diluted mutant DNA solution, namely, an L858R mutation
was detectable in one cancer cell with an L858R mutation of 10
3
normal cells.
EGFR mutations in tumour tissues of patients with lung
cancer
In a total of 469 tumours of the patients who underwent a surgical
resection, EGFR mutations were found in 136 cases (42.2%) with
adenocarcinoma, in one case with large cell carcinoma, and in one
case with pleomorphic carcinoma (Table 1). No other tumours
including squamous cell carcinoma, small cell carcinoma, adeno-
squamous cell carcinoma, carcinoid tumour, and spindle cell
carcinoma had these mutations. An in-frame deletion in exon 19
was found in 62 cases. All these samples showed a clearly separated
band by agarose gel electrophoresis, which thus means a 12 or
15bp deletion. An L858R mutation was found in 77 cases. One case
had mutations in both exons 19 and 21.
Relationship between EGFR mutations and
clinicopathological features in adenocarcinoma
In the 322 cases with adenocarcinoma (Table 2), these EGFR
mutations were more frequently found in female cases than in
male cases (53.1 vs 33.5%, P¼0.0004), in well-differentiated
tumours than in moderately/poorly differentiated tumours (53.8 vs
36.4%, P¼0.0014), and in patients who were never smokers
than in patients who were smokers (57.4 vs 32.1%, Po0.0001). In
smokers, the EGFR mutations were more frequently found in
patients with former smokers than in patients with current
smokers (44.3 vs 25.2%, P¼0.0063). According to the pathological
A
L
Wild-type GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG
mutation CGG
R
Sense primer
Wild-type TC AAG ATC ACA GAT TTT GGG CT
mutation TC AAG ATC ACA GAT TTT GGG CG
L858
Exon 20 21 22
C
B
858
Size
marker
200 bp
100 bp
T:N
NC 1:0 1:1 10–1:1 10–2:110–3:110–4:110–5:1
Figure 2 (A) Mutant-Allele Specific Amplification (MASA) for detection of a point mutation in exon 21. The primer sequences for detection of missense
mutation (L858R) in exon 21 are shown. (B) Sequence analysis of lung cancer cell line (G603). Sequence analysis of lung cancer cell line (G603L) showed
L858R mutation. The L858R mutation was detected in 4% agarose gel electrophoresis. (C) Sensitive assay for detection of L858R by MASA and agarose gel
electrophoresis. DNAs derived from mixture of a cell line G603L (T) and a cell line (N) with wild-type EGFR were applied. A mutant allele was detected in
the mixture of 10
 3 diluted mutant DNA solution.
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sstage, no significant difference was found among the stages.
An L858R mutation in exon 21 was more frequently found in
female than male (P¼0.0272), and in never smoker than smoker
(P¼0.0884). Sixty-two of the 76 female patients with mutations
were never smokers, in which 40 patients (65%) had an L858R
mutation.
We examined the overall survival in relation to EGFR mutations
in patients with adenocarcinoma who did not receive gefitinib
treatment. The 5-year survival rate in the group with EGFR
mutations and in the group without mutations was 73.6 and 64.1%,
respectively, which did not show any statistically significant
difference (P¼0.0652) (Figure 3A). There was no statistically
significant difference in the overall survival curves between the
patients with exon 19 deletion and exon 21 L858R (P¼0.5625)
(Figure 3B).
Relationship between EGFR mutations, K-ras mutation,
and the smoking status in adenocarcinoma patients
In patients with adenocarcinoma, the mutation rate of EGFR in
patients who were never smokers, in patients who had less than a
10 pack-year of smoking index, and in patients who had a 10–20
pack-year of smoking index was 57.4, 66.7, and 56.5%, respectively.
However, EGFR mutations were less observed in patients who
smoked more than 20 pack-year of smoking index, that is, the
EGFR mutation rate in patients with 20–30 pack-year of smoking
index, 30–60, 60–90, and more than 90 was 42.1, 25.0, 16.0, and
8.3%, respectively (Table 3). We analysed the mutations of
K-ras codon 12 in patients with adenocarcinoma, and detected a
mutation in 29 cases (9.0%), but none of them had the EGFR
mutations (Table 2). Five of 129 patients who were never smokers
had the K-ras mutation, while 24 of 193 patients who were current/
former smokers had the mutation, which showed significant
difference (P¼0.0086) (Table 3). In patients who had less than a
60 pack-year of smoking index, 15 of 156 patients (9.6%) had the
K-ras mutation, and in patients who had more than a 60 pack-year
of smoking index, nine of 37 (24.3%) had this mutation, which
showed significant difference (P¼0.0148).
We next examined the relationship between the EGFR mutations
and time duration after the patients had quit smoking (Table 4).
While the mutation rate of current smokers was 25.2%, the
mutation rate of former smokers was 44.3%. In these former
smokers, the mutation rate of the patients who stop smoking for
3–10 years, 10–20 years, and for more than 20 years was 31.3,
40.0, and 52.9%, respectively. The mutation rate of the patients
who had stopped smoking for more than 20 years was almost same
as that of the never smokers. On the other hand, the mutation rate
of the K-ras codon 12 was not dependent on the time duration
after the patients had quit smoking. Among current smokers, the
smoking index was significantly higher in EGFR mutation-negative
patients than in positive patients (P¼0.011). The same results
were also observed in former smokers who stopped smoking less
than 20 years ago, however, no difference in the smoking index
was found in patients who had stopped smoking more than 20
years previously (P¼0.747) (Figure 4).
DISCUSSION
In this study, we established a simple screening method to identify
a deletion of exon 19 and a point mutation of exon 21 of the EGFR
gene, and we detected these mutations in 136 cases (42.2%) with
adenocarcinoma and two cases with other cell types. As shown
in Table 5, in a total of 445 cases with the EGFR mutations from
No. of patients at risk
Mutation (+) 122 71 29 9 2
Mutation (–) 179 84 31 9 2
A
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Figure 3 Kaplan–Meier survival curve for adenocarcinoma patients who
did not receive gefitinib treatment. (A) The overall survival in relation to
EGFR mutations in patients with adenocarcinoma. The five-year survival
rate in the group with EGFR mutations and in the group without mutations
was 73.6% and 64.1%, respectively, which did not show statistically
significant difference (P¼0.0652). (B) There was no statistically significant
difference in the overall survival curves between patients with exon 19
deletion and exon 21 L858R (P¼0.5625).
Table 3 EGFR and K-ras mutations in relation to the smoking index in
patients with adenocarcinoma
Smoking index
(pack-year) n
EGFR
mutation (%)
K-ras
mutation (%)
0 129 74 (57.4) 5 (3.9)
p10 18 12 (66.7) 3 (16.7)
410 p20 23 13 (56.5) 2 (8.7)
420 p30 19 8 (42.1) 1 (5.3)
430 p60 96 24 (25.0) 9 (9.4)
460 p90 25 4 (16.0) 5 (20.0)
490 12 1 (8.3) 4 (33.3)
Total 322 136 (42.2) 29 (9.0)
Table 4 EGFR and K-ras mutations in adenocarcinoma patients who
were current and former smokers
Years after
stopping smoking n
EGFR
mutation (%)
K-ras
mutation (%)
o3
a 123 31 (25.2) 13 (10.6)
X3o10 16 5 (31.3) 5 (31.2)
X10o20 20 8 (40.0) 2 (10.0)
X20 34 18 (52.9) 4 (11.8)
Total 193 62 (32.1) 24 (12.4)
aCurrent smokers are defined persons who stopped smoking less than 3 years
previously.
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had an in-frame deletion in exon 19 and 188 cases had an L858R
mutation in exon 21, namely in 90.0% of cases with EGFR
mutations were detected either in exon 19 as a deletion and in exon
21 as a point mutation of L858R (Table 5) (Huang et al, 2004;
Kosaka et al, 2004; Shigematsu et al, 2005; Sonobe et al, 2005;
Soung et al, 2005; Tokumo et al, 2005). The mutant rate of exons
19 and 21 in all sites of mutations was observed relatively higher in
Japanese patients than Korean patients, although the reason for
this is unknown. Theoretically, these mutations could all result in
conformation changes that lead to an increased activity as well as
TKI sensitivity (Gazdar et al, 2004; Lynch et al, 2004; Paez et al,
2004). In an in vitro study, these two types of EGFR mutants
demonstrated an enhanced TK activity in response to EGF and
increased sensitivity to inhibition by TKI, although the biological
activity between tumours with L858R and those with deletions was
different (Paez et al, 2004; Pao et al, 2004). Therefore, detecting
these two hot spot mutations is very useful to select a specific
population which is sensitive to gefitinib treatment. On the other
hand, a missense mutation in exon 20, especially T790M, showed
gefitinib resistance, as previously reported (Kobayashi et al, 2005;
Pao et al, 2005b). The T790M mutation detected in gefitinib-
resistant tumours, was not found in any untreated tumours from
the same patients. In resected tumours before treatment, only two
of 397 tumours showed the T790M mutation (Toyooka et al, 2005).
This mutation most likely extremely rare, or it might be present in
some tumours at a low frequency at the time of diagnosis.
We used a simple method using PCR and agarose gel
electrophoresis for the detection of a deletion in exon 19, and
this method can detect more than a 12bp deletion. Although the
minimum deletion-size of exon 19 has been reported to be 9bp, in
previous studies (Kosaka et al, 2004; Paez et al, 2004; Shigematsu
et al, 2005), this frequency was extremely low. Therefore, our
method is useful for the screening of in-frame deletions of exon 19.
The mutant-allele-specific amplification (MASA) method is cap-
able of detecting one tumour cell containing genetic changes in a
tumour sample containing thousands of normal cells (Takeda et al,
1993; Hayashi et al, 1994), to detect a point mutation. This method
is very useful when the mutation occurs at a specific site, such as
ras gene mutations which occur at the second base in codon 12
(Sugio et al, 1992; Sugio et al, 1994). Somatic mutations are
detectable by a sequence analysis when the tumour has at least
more than 5% of cancer cells. In some of the resected tissue
samples or biopsy specimens, the ratio of cancer cell is less than
5%, and therefore, sensitive methods to detect such mutations
are necessary. Pan et al (2005) reported sensitive assays based on
a length analysis of fluorescently labeled PCR products for the
detection of two predominant types of EGFR mutations, and thus
showed four cases in which no mutations were apparent by
sequencing. In this study, an L858R mutation was detectable in one
cancer cell of 10
3 normal cells, which is more sensitive than the
previously reported method (Pan et al, 2005). The L858R mutation
in exon 21 occurs in about 20–25% in adenocarcinoma of East
Asian patients, therefore, this MASA method used in this study is
useful for detecting cancer cells with a mutation in sputum, pleural
effusion, or biopsy samples, when only a few cancer cells exist
among a vast number of normal cells. This method might also be
useful for the early detection of an acquired second point mutation
at position 790 during gefitinib treatment (Kobayashi et al, 2005;
Pao et al, 2005c), using appropriate primers. In addition, this
sensitive method is simple and time saving for a routine
pretherapeutic screening. Although the sequence analysis of EGFR
might be necessary for clinical trials using TKI such as gefitinib or
erlotinib, these simple methods established in this study for
detection of exon 19 deletion and exon 21 L858R mutation are very
useful for screening.
Previous studies have demonstrated EGFR mutations to be
associated with adenocarcinoma, well differentiation, female
gender, and never smokers (Kosaka et al, 2004; Lynch et al,
2004; Paez et al, 2004; Pao et al, 2004; Tokumo et al, 2005). In the
present study, we identified EGFR mutations in 136 of 322
adenocarcinomas (42.2%) from Japanese patients, and confirmed
these previous observations. However, we should keep in mind
that the EGFR mutations are observed also in 30% of males and in
25% of current smokers. Adenocarcinomas in East Asian patients
demonstrated a higher occurrence of EGFR mutations than in
Table 5 Incidence of EGFR mutations detected in East Asian patients with lung cancer without gefitinib treatment
Author
Country or
ethnicity
No. of tumours
evaluated
No. of tumours
with EGFR
mutations (%)
No. of mutations of
exon19 deletion or
exon21 L858R (%)
No. of
adenocarcinoma
No. of tumours
with EGFR
mutations (%)
Kosaka et al (2004) Japanese 277 111 (40.1) 101/111 (91.0) 224 110 (49.1)
Tokumo et al (2005) Japanese 120 38 (31.7) 37/38 (97.4) 82 37 (45.1)
Sonobe et al (2005) Japanese 154 60 (39.0) 56/60 (93.3) 108 60 (55.5)
Huang et al (2004) Taiwanese 101 39 (38.6) 33/39 (84.6) 69 38 (55.1)
Soung et al (2005) Korean 153 30 (19.6) 30/30 (100) 69 26 (37.7)
Shigematsu et al (2005) East Asian 361 107 (29.6) 114/134 (85.1)
a 214 102 (47.7)
Present study Japanese 469 138 (29.4) — 322 136 (42.2)
Total 1635 523 (32.0) 371/412 (90.0) 1088 509 (46.8)
aThe total number of patients includes East Asian and other ethnicities.
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Figure 4 Smoking index in relation to the EGFR mutations stratified by
the time duration of quitting smoking. The average smoking index in
patients with EGFR mutations was lower than that in patients without
EGFR mutations, and in the group less than 20 years after they had quit
smoking. However, in the group that had quit smoking more than 20 years
previously, no difference was observed in the average of smoking index
between the patients with EGFR mutations and those without EGFR
mutations.
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et al, 2005). In addition, the in-frame deletions in exon 19 were
significantly more frequent in males while an L858R mutation in
exon 21 was more frequently found in females, which is consistent
with previous reports (Tokumo et al, 2005). We also demonstrated
an inverse correlation between the EGFR mutations and exposure
of tobacco smoking, namely, the smoking dose was closely related
to the rate of EGFR mutations in adenocarcinoma, and we first
showed a correlation between the time duration after the patients
had quit smoking and EGFR mutations. The mutation rate of the
patients who had stopped smoking more than 20 years previously
was almost same as that of the never smokers, and no difference in
the smoking index was observed between the patients with and
without EGFR mutations. The Smoking effect is therefore very
slight for oncogenesis via EGFR mutations of lung adenocarcinoma
for the population who had stopped smoking for more than 20
years previously, whereas K-ras mutations were more frequently
found in smokers as reported previously (Sugio et al, 1992;
Ahrendt et al, 2001). As previously reported (Kosaka et al, 2004),
both mutations between the EGFR and K-ras were also mutually
exclusive in this study. Based on the smoking history of the
patients, the K-ras mutations were more frequently found in
smokers than in never smokers, and in high-dose smokers than in
low-dose smokers. These findings demonstrated that the smoking
dose was related to occurrence of the K-ras mutations.
Tobacco smoking is well-established high-risk factor for lung
cancer, and therefore stopping smoking reduces the risk. In a large
case–control study in the UK, the cumulative risks of lung cancer
by 75 years of age are 15.9% for men who continue to smoke
cigarettes and 9.9, 6.0, 3.0, and 1.7% for those who stopped
smoking around 60, 50, 40, and 30 years of age, respectively. As a
result, stopping smoking before middle age can allow an individual
to avoid more than 90% of the risk attributable to tobacco (Peto
et al, 2000). Although a low expose of smoking reduces the risk for
lung cancer, EGFR mutations are suggested to be related to the
occurrence of lung adenocarcinoma in nonsmoker.
Clinical trials with gefitinib have demonstrated good responses,
particularly in patients with adenocarcinoma, and most frequently
in females, nonsmokers, and East Asian patients (Fukuoka et al,
2003; Kris et al, 2003). Subsequently, it was demonstrated that the
tumours with EGFR mutations are highly sensitive to gefitinib
(Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004) and the patients
with EGFR mutations survived for a longer period after gefitinib
treatment (Han et al, 2005; Mitsudomi et al, 2005). We also
sequenced exons 18–23 of the EGFR gene of tumours in 20
patients with NSCLC who had been treated with gefitinib, and nine
tumours had the mutations. Seven of nine cases with mutated
types showed high sensitivity to gefitinib, and the patients with
EGFR mutations had a more favourable prognosis than those with
wild type after gefitinib treatment (P¼0.033) (Uramoto et al,
2006). In previous clinical reports, gefitinib was effective in a few
patients without EGFR mutations, thus indicating that not only
mutations in TK domain but other mechanisms such as
amplification, aberrant signaling may activate AKT and sensitise
tumour cells to EGFR inhibitors (Amann et al, 2005; Takano et al,
2005). Although EGFR mutations itself is not a predictor for a
better survival in adenocarcinoma patients as shown in both the
present study and a previous study (Kosaka et al, 2004), EGFR
mutations were good predictor of the clinical benefit with patients
with gefitinib treatment in such patients.
In conclusion, our established methods are thus considered to
be very useful for identifying a deletion of exon 19 and a point
mutation (L858R) of exon 21 of the EGFR gene as a screening. The
mutations within the tyrosine kinase domain of EGFR associated
with gefitinib sensitivity were thus found to specifically occur in
lung adenocarcinoma patients with a low exposure of tobacco
smoking.
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